Form 8-K Filing by Repligen Corporation

Repligen Corporation has announced the expiration of the HSR Waiting Period for its acquisition of BioLife Solutions, Inc. The acquisition, valued at $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share, is proceeding, subject to other customary closing conditions, including BioLife stockholder adoption of the Merger Agreement. A special meeting for BioLife stockholders is scheduled for October 5, 2026. The report also includes cautionary statements regarding forward-looking statements, potential risks, and uncertainties associated with the merger, as well as information on where to find additional details about the transaction and the involved parties. The company has filed a registration statement which includes a proxy statement/prospectus for the merger.